Oncolines

Executive Summary

Oncolines is a Netherlands-based precision oncology service provider that accelerates the development of improved and novel therapies by enabling the right patient population to be identified faster. Founded in 2013, the company offers a comprehensive suite of services including cancer cell line profiling, proliferation assays, drug combination studies, and bioinformatics analysis. These capabilities help pharmaceutical and biotech clients optimize drug candidates, identify biomarkers, and design more effective clinical trials. Oncolines’ approach addresses a critical bottleneck in oncology drug development: the need to match therapies with patients who are most likely to benefit. By leveraging a broad panel of cancer cell lines and high-throughput screening, the company supports both early-stage discovery and late-stage translational research. As precision oncology becomes increasingly central to cancer care, Oncolines is well-positioned to serve as a key partner for drug developers seeking to enhance the efficiency and success rate of their programs. With a focus on providing actionable, high-quality data, the company contributes to reducing the cost and time required to bring new treatments to market, ultimately improving outcomes for cancer patients worldwide.

Upcoming Catalysts (preview)

• Q3 2026Launch of Expanded Cell Line Panel for Rare Cancers70% success
• Q4 2026Strategic Partnership with a Major Pharmaceutical Company50% success
• Q2 2026Publication of Validation Data in Peer-Reviewed Journal80% success